文献速递癫痫

布美他尼治疗新生儿惊厥的初步随机对照双盲试验

A Pilot Randomized, Controlled, Double-Blind Trial of Bumetanide to Treat Neonatal Seizures.
PubMed 文献 · Ann Neurol · 2020-12-03

在缺乏对照试验的背景下,这项随机双盲剂量递增试验将苯巴比妥后仍有EEG确诊惊厥的33-44周新生儿分配至安慰剂对照组或布美他尼0.1/0.2/0.3mg/kg组。结果显示布美他尼组惊厥负担中位数更高(3.1 vs 1.2 min/h, p=0.006),但给药后0-4小时和2-4小时惊厥负担较基线下降幅度显著大于对照组(均p<0.01),利尿是唯一显著不良事件。

要点

  • 布美他尼联合苯巴比妥可额外降低惊厥负担,但需平衡惊厥严重程度。
  • 布美他尼组利尿发生率48% vs 对照组13%(p=0.02),为唯一显著不良事件。
  • 药代动力学变异大且受低温治疗影响,未来试验应设对照组并平衡惊厥严重度。

核心结论

  • 布美他尼在苯巴比妥基础上额外降低惊厥负担,且未增加严重不良事件。
  • 疗效确证尚需适当把握度的3期试验。

研究设计与样本

  • 随机、双盲、剂量递增、多中心试验,纳入33-44周胎龄新生儿。
  • 苯巴比妥≥20且<40mg/kg后EEG确诊惊厥者随机接受安慰剂(对照n=16)或布美他尼0.1/0.2/0.3mg/kg(治疗n=27)。

主要发现

  • 治疗组惊厥负担中位数3.1 min/h,对照组1.2 min/h(p=0.006)。
  • 给药后0-4小时和2-4小时惊厥负担较2小时基线下降幅度治疗组显著大于对照组(均p<0.01)。
  • 利尿发生率治疗组48% vs 对照组13%(p=0.02)。
  • 死亡:治疗组1例(4%),对照组3例(19%)(p=0.14)。
  • 存活者中听力损害:治疗组2/26(8%),对照组0/13。

关键数值与推荐

  • 纳入标准:胎龄33-44周、有惊厥风险或惊厥、苯巴比妥≥20且<40mg/kg后EEG确诊惊厥。
  • 治疗分组:安慰剂或布美他尼0.1、0.2、0.3mg/kg。
  • 惊厥负担比较:治疗组中位数3.1 min/h vs 对照组1.2 min/h(p=0.006)。
  • 惊厥负担下降:给药后0-4小时和2-4小时较基线下降幅度治疗组显著大于对照组(均p<0.01)。
  • 不良事件:利尿48% vs 13%(p=0.02);死亡4% vs 19%(p=0.14)。

临床怎么用

  • 布美他尼可作为苯巴比妥难治性新生儿惊厥的附加治疗选择,但需监测利尿。
  • 药代动力学变异大且受低温治疗影响,用药时需考虑低温状态。
  • 未来临床试验应设置对照组并平衡惊厥严重程度。

局限性

  • 为初步试验,样本量小(治疗27例、对照16例),疗效确证需3期试验。
  • 治疗组基线惊厥负担显著高于对照组,可能影响结果解释。
  • 药代动力学高度变异且受低温治疗影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In the absence of controlled trials, treatment of neonatal seizures has changed minimally despite poor drug efficacy. We tested bumetanide added to phenobarbital to treat neonatal seizures in the first trial to include a standard-therapy control group. METHODS: A randomized, double-blind, dose-escalation design was employed. Neonates with postmenstrual age 33 to 44 weeks at risk of or with seizures were eligible. Subjects with electroencephalography (EEG)-confirmed seizures after ≥20 and <40mg/kg phenobarbital were randomized to receive additional phenobarbital with either placebo (control) or 0.1, 0.2, or 0.3mg/kg bumetanide (treatment). Continuous EEG monitoring data from ≥2 hours before to ≥48 hours after study drug administration (SDA) were analyzed for seizures. RESULTS: Subjects were randomized to treatment (n = 27) and control (n = 16) groups. Pharmacokinetics were highly variable among subjects and altered by hypothermia. The only statistically significant adverse event was diuresis in treated subjects (48% vs 13%, p = 0.02). One treated (4%) and 3 control subjects died (19%, p = 0.14). Among survivors, 2 of 26 treated subjects (8%) and 0 of 13 control subjects had hearing impairment, as did 1 nonrandomized subject. Total seizure burden varied widely, with much higher seizure burden in treatment versus control groups (median = 3.1 vs 1.2 min/h, p = 0.006). There was significantly greater reduction in seizure burden 0 to 4 hours and 2 to 4 hours post-SDA (both p < 0.01) compared with 2-hour baseline in treatment versus control groups with adjustment for seizure burden. INTERPRETATION: Although definitive proof of efficacy awaits an appropriately powered phase 3 trial, this randomized, controlled, multicenter trial demonstrated an additional reduction in seizure burden attributable to bumetanide over phenobarbital without increased serious adverse effects. Future trials of bumetanide and other drugs should include a control group and balance seizure severity. ANN NEUROL 2021;89:327-340.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Soul JS, Bergin AM, Stopp C, et al. A Pilot Randomized, Controlled, Double-Blind Trial of Bumetanide to Treat Neonatal Seizures. Ann Neurol. 2020. PMID: 33201535. doi:10.1002/ana.25959

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。